Publications
5600 Results
- Journal / Conference
- J Clin Oncol 41, 2023 (suppl 16; abstr 6527); ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), poster session
- Year
- 2023
- Research Committee(s)
- Cancer Care Delivery
Association of Baseline Measures of Socioeconomic Deprivation and Healthcare Utilization in Patients Enrolled in SWOG Cancer Clinical Trials
- Journal / Conference
- J Clin Oncol 41, 2023 (suppl 16; abstr TPS5103); ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), TIP poster session
- Year
- 2023
- Research Committee(s)
- Genitourinary, Prevention, Screening, and Surveillance, Prevention, Screening, and and Surveillance
- Study Number(s)
- S1823
SWOG S1823/CCTG GCC1 - Translational Observational Investigational Study of the Liquid Biomarker microRNA 371a-3p in Newly Diagnosed Germ Cell Tumours - Real-World Trial Design, Rapid Accrual, and Robust Secondary Use of Data Opportunities
- Journal / Conference
- J Clin Oncol 41, 2023 (suppl 16; abstr 1565); ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), poster session
- Year
- 2023
- Research Committee(s)
- Cancer Care Delivery
Impact of COVID-19 Pandemic Mitigation Strategies on Industry and NCI Cancer Treatment Trials
- Journal / Conference
- J Clin Oncol 41, 2023 (suppl 16; abstr 4546); ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), poster session
- Year
- 2023
- Research Committee(s)
- Genitourinary
- Study Number(s)
- S0931
Adjuvant everolimus in patients (Pts) with localized non-clear cell renal cell carcinoma (RCC): Subgroup analysis from the Everest trial (SWOG S0931)
- Journal / Conference
- J Clin Oncol 41, 2023 (suppl 16; abstr 8037); ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), poster
- Year
- 2023
- Research Committee(s)
- Myeloma
- Study Number(s)
- S0777
Adjusted indirect treatment comparison of progression-free survival (PFS) associated with DRd and VRd based on MAIA and SWOG S0777 individual patient-level data
- Journal / Conference
- J Clin Oncol 41, 2023 (suppl 16; abstr e18529); ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), publication only
- Year
- 2023
- Research Committee(s)
- Cancer Care Delivery
Diversity, equity, and inclusion (DEI) champions: Lessons learned and implications for future programming to support cancer clinical trials
- Journal / Conference
- J Clin Oncol 41, 2023 (suppl 16; abstr 5070); ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), poster
- Year
- 2023
- Research Committee(s)
- Genitourinary
- Study Number(s)
- SWOG-9346
Assessing PSA levels as prognostic of overall survival (OS) in men with metastatic hormone-sensitive prostate cancer (mHSPC)
- Journal / Conference
- J Clin Oncol 41, 2023 (suppl 16; abstr 5073); ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), poster
- Year
- 2023
- Research Committee(s)
- Genitourinary
- Study Number(s)
- SWOG-9346
The relationship between a priori defined prognostic risk groups and overall survival (OS) in men with metastatic hormone sensitive prostate cancer (mHSPC)
- Journal / Conference
- Cancer Epidemiology, Biomarkers, and Prevention Sep 1;32(9):1242-1248
- Year
- 2023
- Research Committee(s)
- Prevention, Screening, and and Surveillance
- PMID
- PMID37342060
- PMC
- PMC10527950
- Study Number(s)
- S0000
Relationship between ABO blood group alleles and pancreatic cancer is modulated by secretor (FUT2) genotype, but not Lewis antigen (FUT3) genotype
- Journal / Conference
- Cancer Research Aug 1;83(15):2572-2583
- Year
- 2023
- Research Committee(s)
- Prevention, Screening, and Surveillance, Prevention, Screening, and and Surveillance
- PMID
- PMID37249599
- PMC
- PMC10391330
- Study Number(s)
- S0000